ImmunoFoco Biotech Secures RMB 100 Million Series A Financing Led by Delian Capital to Advance Solid Tumor CAR-T Therapies

Recently, Immunofoco (Shanghai Immunofoco Biotechnology Co., Ltd.) announced the completion of its Series A financing round worth hundreds of millions. This round was led by Delian Capital, with participation from Shenzhen Yuancube Financial Services Co., Ltd. and Shenzhen Qianhai Luojia Prudence Asset Management Co., Ltd., while KinghandCapital Management (Beijing) CO., Ltd. continued to increase its investment. The funds raised will mainly be used for the company’s multiple IIT clinical studies and the China-U.S. application for its first IND project.

Immunofoco is an innovative enterprise that utilizes an immune cell therapy technology platform and combines clinical innovation methods to develop new solid tumor treatment drugs. It commenced operations in Zhangjiang, Shanghai, in September 2020. The company was co-founded by a team of scientists and industry elites, with a founding team covering industry, academia, research, and medicine. Core members have successfully driven the marketing application of China’s first CAR-T drug, boasting extensive experience in cell drug development and industrialization. The company has established the "Pericruiser®" technology platform, targeting two major industry pain points: solid tumors and universal cell therapy products, initially focusing on gastrointestinal cancer indications. In terms of progress, Immunofoco advanced its first project into the IIT clinical trial stage in less than a year and plans to file an IND product in 2022.